ZELTIA NEWS: Aplidin®, Yondelis®, PM01183 and PM060184 highlighted at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) .
Aplidin® confirmed as a first-in-class drug, with the mechanism of action highlighted for the first time, showing it targets the eEF1a protein in tumour cells .
A new study supports the clinical use of PM01183 in Ewing's sarcoma as directed treatment, either alone or in combination with irinotecan .
PM060184 evidences notable antitumour activity in vivo in a range of xenografted tumour types .
Additional Yondelis® data to be presented showing a synergistic combination with Olaparib in breast cancer tumour cell lines .
San Diego, 7 April 2014.- PharmaMar, a biotechnology subsidiary of Grupo Zeltia .
...